We now offer Remdesivir to treat Covid-19 positive patients who have severe symptoms. Remdesivir is an FDA approved treatment for adult and adolescent patients over the age of 12.
Remdesivir as Covid-19 Treatment
Remdesivir is an FDA approved antiviral medication used to treat Covid-19. This drug works by binding to specific viral RNA and preventing it from replicating, which reduces viral load in the body. This, in turn, helps prevent symptoms from becoming severe or requiring hospitalization, as well as improve symptoms faster.
Studies have shown that this drug can:
Who should consider receiving Remdesivir treatment?
Remdesivir is approved for adults and children over the age of 12 and may be beneficial for individuals who:
- Have tested positive for Covid-19
- Have moderate or severe symptoms
- Are vaccinated OR unvaccinated
- Are immunocompromised
- Are taking immunosuppressants
- Are at high risk for developing complications
- Have certain chronic medical conditions
Hear From Our Clients
Frequently Asked Questions
What is Remdesivir?
Remdesivir is an anti-viral medication that inhibits viral replication, which helps reduce viral load in the body. This, in turn, helps prevent symptoms from becoming severe and may help patients recover more quickly. Read More at www.covid19treatmentguidelines.nih.gov.
Who is eligible for this treatment?
Remdesivir is FDA approved for use in adults and children over the age of 12. Remdesivir is also available under FDA’s emergency use authorization (FDA) in hospitalized children under the age of 12.
What side effects can you expect?
Like other medications, remdesivir can cause several potential symptoms, including:
- Inflammation and redness at the injection site
- Pain or tenderness at the injection site
- Gastrointestinal issues (eg. nausea, vomiting)
IV treatments are closely monitored by our nurses to ensure patient safety during the infusion.
Clinical Trials
There are several clinical trials evaluating the use of Remdesivir for the treatment of COVID-19. Please see ClinicalTrials.gov for the latest information.
Considerations in Children
Remdesivir is available through an FDA EUA for the treatment of Covid-19 in hospitalized children under the age of 12 weighing 3.5 kg to <40 kg. There are insufficient data on the safety and efficacy of using remdesivir for COVID-19 in this population because they have not yet been evaluated in clinical trials.
